溴隐亭; 2-溴-12'-羟基-5'-alpha-异丁基-2'-异丙基麦角胺-3',6',18-三酮

  • 基本信息
  • 制备方法及用途
  • 物化性质
  • 安全信息
  • 毒理性
  • 结构与计算化学
  • 上游产品

溴隐亭; 2-溴-12'-羟基-5'-alpha-异丁基-2'-异丙基麦角胺-3',6',18-三酮 基本信息

中文名称:
溴隐亭; 2-溴-12'-羟基-5'-alpha-异丁基-2'-异丙基麦角胺-3',6',18-三酮 
中文别名:
溴隐亭;
溴麦角环肽;
溴麦角隐亭;
溴麦亭;
溴代麦角隐亭碱;
溴隐亭(2-溴-ALPHA-麦角环肽);
2-溴-ALPHA-麦角环肽;
2-溴-12'-羟基-5'-ALPHA-异丁基-2'-异丙基麦角胺-3',6',18-三酮 
英文名称:
Ergotaman-3',6',18-trione,2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'a)-
英文别名:
bromocriptine;
Bromoergocryptine;
Ergoset;
Bromergocryptine;
Bromocriptin;
Bromoergocriptine;
Bromocriptinum;
Bromocryptine 
CAS No.:
25614-03-3
分 子 式:
C32H40BrN5O5
分 子 量:
654.59
精确分子量:
653.22100
PSA:
118.21000
EINECS:
247-128-5
InChI:
The Key: OZVBMTJYIDMWIL-AYFBDAFISA-N
风险术语:
R20/21/22
分子结构式:
SDS:
查看

溴隐亭; 2-溴-12'-羟基-5'-alpha-异丁基-2'-异丙基麦角胺-3',6',18-三酮 制备方法及用途

制备方法

由麦角隐亭和N-溴丁二酸亚胺反应得到。

合成制备方法

由麦角隐亭和N-溴丁二酸亚胺反应得到。

用途简介

本品具有多巴胺受体的兴奋作用。可透过血脑屏障,进入中枢神经内,激动多巴胺受体和抑制催乳素及生长激素分泌作用。临床用于帕金森氏症、肢端肥大症和乳溢症等。

用途

本品具有多巴胺受体的兴奋作用。可透过血脑屏障,进入中枢神经内,激动多巴胺受体和抑制催乳素及生长激素分泌作用。临床用于帕金森氏症、肢端肥大症和乳溢症等。

溴隐亭; 2-溴-12'-羟基-5'-alpha-异丁基-2'-异丙基麦角胺-3',6',18-三酮 物化性质

外观与性状:
白色结晶粉末
密度:
1.52 g/cm3
沸点:
891.3ºC at 760 mmHg
闪点:
492.8ºC
折射率:
1.696
蒸汽压:
4.15E-34mmHg at 25°C
存储条件/存储方法:
库房通风干燥低温
其它信息:

1性状:白色结晶性粉末。

2熔点:215-218℃(分解)。

溴隐亭; 2-溴-12'-羟基-5'-alpha-异丁基-2'-异丙基麦角胺-3',6',18-三酮 安全信息

危险类别码:
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed .
安全说明:
S45
危险标志:
Xn,Xi

溴隐亭; 2-溴-12'-羟基-5'-alpha-异丁基-2'-异丙基麦角胺-3',6',18-三酮 毒理性

CHEMICAL IDENTIFICATION

RTECS NUMBER :
KE7625000
CHEMICAL NAME :
Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpr opyl)-, (5'-alpha)-
CAS REGISTRY NUMBER :
25614-03-3
LAST UPDATED :
199703
DATA ITEMS CITED :
38
MOLECULAR FORMULA :
C32-H40-Br-N5-O5
MOLECULAR WEIGHT :
654.68

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
6 mg/kg/60D-I
TOXIC EFFECTS :
Sense Organs and Special Senses (Olfaction) - effect, not otherwise specified
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
72 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>800 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
200 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
>1 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
12 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
7 gm/kg/2Y-C
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Reproductive - Tumorigenic effects - uterine tumors
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2423 ug/kg
SEX/DURATION :
lactating female 3 week(s) post-birth
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1500 ug/kg
SEX/DURATION :
lactating female 9 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Maternal Effects - postpartum
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1500 ug/kg
SEX/DURATION :
lactating female 15 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Maternal Effects - postpartum
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1750 ug/kg
SEX/DURATION :
lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Maternal Effects - postpartum
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
21700 ug/kg
SEX/DURATION :
female 28 week(s) pre-mating female 1-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - respiratory system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
3500 ug/kg
SEX/DURATION :
female 14 day(s) pre-mating female 1-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
11900 ug/kg
SEX/DURATION :
female 77 day(s) pre-mating female 1-42 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
11200 ug/kg
SEX/DURATION :
female 44 day(s) pre-mating female 1-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
2800 ug/kg
SEX/DURATION :
female 24-52 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - body wall
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
70 mg/kg
SEX/DURATION :
female 13-19 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - behavioral
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
1950 ug/kg
SEX/DURATION :
female 5-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
5100 ug/kg
SEX/DURATION :
lactating female 3 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Maternal Effects - postpartum
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
17500 ug/kg
SEX/DURATION :
male 35 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
88 mg/kg
SEX/DURATION :
female 1-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Fertility - other measures of fertility
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
8125 ug/kg
SEX/DURATION :
female 6-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
84 mg/kg
SEX/DURATION :
lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
200 mg/kg
SEX/DURATION :
female 50 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Fertility - female fertility index (e.g. # females pregnant per # sperm positive females; # females pregnant per # females mated)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
212 mg/kg
SEX/DURATION :
female 32 day(s) pre-mating female 21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
4 mg/kg
SEX/DURATION :
male 10 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
750 ug/kg
SEX/DURATION :
female 43-48 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - abortion
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
600 ug/kg
SEX/DURATION :
female 42-47 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - abortion
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
8 mg/kg
SEX/DURATION :
female 27-30 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - other effects to embryo
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
400 ug/kg
SEX/DURATION :
male 50 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - testes, epididymis, sperm duct
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
3 mg/kg
SEX/DURATION :
male 84 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - prostate, seminal vesicle, Cowper's gland, accessory glands Reproductive - Paternal Effects - other effects on male
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
75200 ug/kg
SEX/DURATION :
female 42-49 week(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Maternal Effects - postpartum
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
22400 ug/kg
SEX/DURATION :
female 42-44 week(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects Endocrine - estrogenic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
1 mg/kg
SEX/DURATION :
female 23 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - parturition Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)

MUTATION DATA

TEST SYSTEM :
Rodent - rat
DOSE/DURATION :
4 mg/kg
REFERENCE :
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941- Volume(issue)/page/year: 36,2223,1976 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X6252 No. of Facilities: 9 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 339 (estimated) No. of Female Employees: 170 (estimated)

溴隐亭; 2-溴-12'-羟基-5'-alpha-异丁基-2'-异丙基麦角胺-3',6',18-三酮 分子结构与计算化学数据

分子结构数据

1、  摩尔折射率:165.35

2、  摩尔体积(cm3/mol):429.3

3、  等张比容(90.2K):1257.7

4、  表面张力(dyne/cm):73.6

5、  极化率(10-24cm3):65.55

计算化学数据

1.疏水参数计算参考值(XlogP):3.8

2.氢键供体数量:3

3.氢键受体数量:6

4.可旋转化学键数量:5

5.互变异构体数量:8

6.拓扑分子极性表面积118

7.重原子数量:43

8.表面电荷:0

9.复杂度:1230

10.同位素原子数量:0

11.确定原子立构中心数量:6

12.不确定原子立构中心数量:0

13.确定化学键立构中心数量:0

14.不确定化学键立构中心数量:0

15.共价键单元数量:1

溴隐亭; 2-溴-12'-羟基-5'-alpha-异丁基-2'-异丙基麦角胺-3',6',18-三酮 上游产品

推荐供应商更多供应商>>

山东默派生物科技有限公司

产品介绍:
产品名称:溴隐亭 Cas号:25614-03-3 纯度:99% 包装信息:1kg 价格:洽谈
联系方式:
联系人:张经理 电话:13070690626 手机:13070690626